• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA warns Steris on improper marketing

FDA warns Steris on improper marketing

February 15, 2011 By MedCity News

Steris

Decontamination technologies maker Steris Corp. (NYSE:STE) struggles with the U.S. Food and Drug Administration continue, as the agency cited the company for making improper marketing claims about several steam-sterilization devices.

The FDA sent Steris a warning letter, dated Feb. 9, alleging that the Mentor, Ohio-based company mis-branded its devices by making claims about the devices’ capabilities that were not cleared by the FDA as part of Steris’ 510(k) applications for market clearance.

“Our recent review of your labeling, brochures and other materials used to promote your products and your website finds that you are making claims that were determined to be unacceptable during the review of your 510(k) submissions,” the FDA said in the warning letter.

MedCity News logo

FDA warning letters are considered by the FDA to be informal and advisory and don’t necessarily indicate that the FDA intends to take any punitive action against recipients. The FDA asked Steris to respond within 15 days with a list of the steps it plans to take to correct the violations.

“Steris is reviewing this matter and expects to respond within that time period,” the company said in a Securities & Exchange Commission filing. “We do not believe that the impact of this event will have a material adverse effect on our financial results.”

Specifically, several of the violations cited by the FDA relate to chemical indicators, which are used, for example, to indicate whether the presence of chemicals is detected on a medical instrument. In one instance, the FDA cited Steris for claiming that chemical indicators are “designed to measure sterility success.”

The FDA objected to the claim because it said the indicators do not measure “success,” rather they measure “only that a particular sterilizer cycle met the designated physical parameters for that cycle,” according to the warning letter.

Steris would need to submit a new 510(k) application to be cleared to make the claims it did in the marketing materials, according to the warning letter.

Several events over the past year or so have likely strained the relationship between Steris and the FDA — behind closed doors, at least.

Most significantly, Steris is still operating in the shadow of events brought on by a December 2009 federal safety alert about its flagship System 1 sterilization device. The FDA warned that the system could cause harm to patients. The company has been working to transition customers to its new System 1E product, but recently downgraded its full-year sales projection due to apparent delays in FDA clearance of an accessory part.

Additionally, the company received a warning letter late last year regarding rec0rd-keeping and quality-control violations at a Texas plant.

Steris’ share price was down about 1.5 percent to $34.16 in late trading Tuesday.

Filed Under: Business/Financial News, Food & Drug Administration (FDA), News Well, Sterilization / Calibration Tagged With: Steris Corp., Warning Letter

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy